Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Recruiting now · Phase 1

Conditions studied: Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms

In brief

An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Key facts

Study ID

NCT06128148

Run by

Guangzhou JOYO Pharma Co., Ltd

People needed

101

Starts

2022-05-04

Expected to finish

2027-12-30

Last updated by the study team

2025-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sun Yat-Sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.